Sun Q3 Profits Dive, Halol Resolution Stays Pivotal To Trigger Reset
Executive Summary
Sun Pharma reported a sharp decline in Q3 profits, dented by tax adjustments related to changes in US tax rates and continuing pricing pressures there. With Q4 revenues expected to to be "similar” to Q3, all eyes are on the Halol site making the compliance cut and the upcoming PDUFA date for Sun’s psoriasis asset.
You may also be interested in...
Sun’s Key Halol Plant Flunks FDA Inspection Again
The US FDA has flagged more issues at Indian firm Sun Pharma’s largest manufacturing plant in Halol but analysts are hoping the infractions are minor and that the Indian facility will get the regulatory green light soon, ending a blacklist on the factory supplying new products to the US.
US Pricing Squeeze Clouds Sun Pharma Q2; Site Re-Inspection Critical
Further evidence of the impact of pricing pressure in the US was provided when Sun Pharma reported a sharp fall in profits in Q2 (although it beat the expectations of some analysts). Sun also expects a delay in EU approval for its late stage psoriasis asset, tildrakizumab, but US approval timelines appear unchanged, at least for now.
Sun Primes Late-Stage Psoriasis Asset With Samsung Manufacturing Deal
Sun Pharma has firmed up a manufacturing pact for tildrakizumab with Samsung BioLogics, securing supplies of its late-stage psoriasis asset in an increasingly competitive segment. The deal also underscores Samsung’s expanding stature as a frontline CMO in the biologics space.